Development of Novel Ex Vivo Examination Kit To Detect HER2 Protein Overexpression in Gastric Cancer

Development of Novel Ex Vivo Examination Kit To Detect HER2 Protein Overexpression in Gastric Cancer - Development of Novel Ex Vivo Examination Kit To Detect HER2 Protein Overexpression in Gastric Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031515

Enrollment

100

Registered

2018-03-01

Start date

2016-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have or are suspected to have gastric cancer and get esophagogastroduodenoscopic examination at Kyoto University Hospital.

Exclusion criteria

Exclusion criteria: Patients with high risk of bleeding after endoscopic biopsy.

Design outcomes

Primary

Measure	Time frame
Concordance rate of the examination results of HER2 overexpression obtained by our novel kit and current procedure (immunohistochemistry and in situ hybridization) using endoscopic biopsy specimens of gastric cancer,	—

Countries

Japan

Contacts

Public ContactMasahiro Yoshioka

Kyoto University Hospital Therapeutic Oncology

yoshi0ka@kuhp.kyoto-u.ac.jp075-751-3111

Outcome results